Product image of Maexeni 30 (Ethinylestradiol, Levonorgestrel) supplied by GNH India

Maexeni 30

Active Ingredient:
Ethinylestradiol, Levonorgestrel
Origin:
EU

Maexeni 30 (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol, the active ingredient in Maexeni 30, is a combined oral contraceptive presented as an oral tablet for oral use. It prevents pregnancy by inhibiting ovulation and altering cervical mucus in women of reproductive age.
GNH India supplies Maexeni 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Hormosan Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Maexeni 30, a combined hormonal contraceptive, is used within the family planning and menstrual regulation pathways.

  • Contraception: provides reliable prevention of pregnancy when taken as prescribed.
  • Menstrual cycle regulation: helps achieve more predictable menstrual bleeding patterns.
  • Acne improvement: may reduce androgen‑related acne in some users.

How It Works

  • Ethinylestradiol and levonorgestrel act together to suppress the hypothalamic‑pituitary‑gonadal axis, reducing the secretion of luteinising hormone (LH) and follicle‑stimulating hormone (FSH). This inhibition prevents follicular development and ovulation. The estrogen component stabilises the endometrium, while the progestogen thickens cervical mucus and induces endometrial changes that together hinder fertilisation and implantation.

Side Effects

Maexeni 30 may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Nausea: mild stomach upset, especially when starting therapy.
  • Headache: occasional tension‑type headaches.
  • Breast tenderness: temporary swelling or discomfort.
  • Spotting or breakthrough bleeding: irregular light bleeding between periods.
  • Weight fluctuation: minor changes in fluid retention.
  • Mood changes: mild irritability or mood swings.

Serious or Rare Side Effects

  • Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism.
  • Hypertension: new‑onset high blood pressure.
  • Liver dysfunction: abnormal liver enzyme elevations.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Gallbladder disease: gallstones or biliary colic.

Precautions & Warnings

Before prescribing Maexeni 30, clinicians should assess individual risk factors and counsel patients on safe use.

  • Smoking status: avoid use in women over 35 who smoke due to increased cardiovascular risk.
  • Cardiovascular disease: contraindicated in patients with history of thromboembolic events.
  • Liver disease: use with caution in active liver disease or dysfunction.
  • Migraine with aura: contraindicated because of heightened stroke risk.
  • Pregnancy testing: confirm non‑pregnant status before initiation.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Maexeni 30 can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Antiepileptics (e.g., carbamazepine, phenytoin): may markedly reduce contraceptive effectiveness.
  • Rifampin and other potent enzyme inducers: can lower hormone levels, increasing pregnancy risk.
  • Certain antiretrovirals (e.g., efavirenz): may diminish contraceptive protection.

Moderate Interactions (Monitor Closely)

  • Antifungals (e.g., ketoconazole): may increase hormone concentrations, raising side‑effect potential.
  • St. John’s Wort: may modestly decrease efficacy; monitor for breakthrough bleeding.
  • Diuretics: may affect fluid balance and blood pressure; observe for hypertension.

Frequently Asked Questions

Maexeni 30 is a combined oral contraceptive tablet containing ethinylestradiol and levonorgestrel. It is prescribed to prevent pregnancy in women of reproductive age and may also help regulate menstrual cycles and improve acne associated with androgen excess.

Ethinylestradiol, the estrogen component, works together with levonorgestrel to suppress the hypothalamic‑pituitary‑gonadal axis, reducing LH and FSH release. This prevents ovulation, stabilises the endometrium, and, together with the progestogen, creates cervical mucus that is hostile to sperm.

The dosing regimen for Maexeni 30 is determined by the prescribing clinician. Typically, it is taken as a daily oral tablet following the specific cycle schedule indicated on the prescription label.

Maexeni 30 is contraindicated during pregnancy because it is intended to prevent conception. If pregnancy occurs, the tablet should be discontinued. Limited data exist for use while breastfeeding; clinicians usually advise against use until after the postpartum period unless benefits outweigh risks.

To order Maexeni 30, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maexeni 30 contains the standard dose combination of ethinylestradiol and levonorgestrel, which is comparable to many other combined oral contraceptives. Its efficacy, safety profile and side‑effect spectrum are similar to other EE/LNG products, with differences mainly in tablet branding, packaging and regional regulatory approvals.

Maexeni 30 tablets should be stored at ambient temperature, below 25 °C. Keep them in the original blister pack, protect from moisture, heat and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Maexeni 30 is taken orally, usually once daily at the same time each day. The tablet is swallowed whole with water and should be started according to the prescribing schedule, often on the first day of the menstrual period or as directed by a healthcare professional.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis (stroke or myocardial infarction), hypertension, and severe liver disease. Patients should be educated to seek immediate medical attention if they experience unexplained leg pain, chest pain, shortness of breath, or severe headache.

Maexeni 30 is contraindicated in women who are pregnant, have a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or who are smokers over the age of 35. It should also be avoided in individuals with known hypersensitivity to ethinylestradiol, levonorgestrel or any tablet excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT